Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

Journal of the National Cancer Institute - 6 Dec 2006

Cusatis George, Gregorc Vanesa, Li Jing, Spreafico Anna, Ingersoll Roxann G, Verweij Jaap, Ludovini Vienna, Villa Eugenio, Hidalgo Manuel, Sparreboom Alex, Baker Sharyn D

Abstract excerpt

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase with activity in non-small-cell lung cancer. Diarrhea and skin toxicity are prominent gefitinib-related adverse events that potentially limit its use. Gefitinib is a substrate for ABCG2 (ABCP, BCRP, MXR), a polymorphic efflux transporter protein that is highly expressed in the intestines and liver. Here we investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to ATP-Binding Cassette Transporters

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Proteins

Share to Quinazolines

Source

Identifiers

PMID: 17148776
DOI: 10.1093/jnci/djj469

Genes

ABCG2
EGFR
ABCB1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.PMID 17148776Read ↗

Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.Semantic proximity Read ↗

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Semantic proximity Read ↗

Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacogenomic importance of ABCG2.Semantic proximity Read ↗

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.Semantic proximity Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study.Semantic proximity Read ↗

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.Semantic proximity Read ↗

Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.Semantic proximity Read ↗

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.Semantic proximity Read ↗

Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.